All‐cause mortality ‐ short‐term · health problem or population
It is very uncertain whether summary of findings table ‐ Psychological treatment changes all‐cause mortality ‐ short‐term compared with control (very low certainty).
1 finding from 1 review
All‐cause mortality, neonates, IgM‐enriched polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, IgM‐enriched polyclonal IVIG compared with placebo or no intervention (low certainty).
1 finding from 1 review
Mortality In the early postoperative period (≤ 30 days) · adult participants undergoing cardiac and major abdominal surgery
It is very uncertain whether preoperative inspiratory muscle training changes all‐cause mortality within 30 days during postoperative period compared with usual care, non‐exercise intervention (very low certainty).
1 finding from 1 review
All‐cause mortality within 3 months · people with acute ischemic stroke
Thrombo‐aspiration alone showed no clear difference in all‐cause mortality within 3 months compared with stent‐retrieval thrombectomy alone (high certainty).
1 finding from 1 review
All‐cause mortality or other serous adverse events of the newborn
1 finding from 1 review
All‐cause mortality or other serous adverse events of the mothers
1 finding from 1 review
All‐cause mortality during hospital stay · preterm or low birth weight infants with PDA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality during hospital stay · preterm or low birth weight infants with PDA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality during hospital stay · preterm or low birth weight infants with PDA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality during hospital stay · preterm infants with PDA
Prophylactic administration of paracetamol showed no clear difference in all‐cause mortality during initial hospital stay (by clinical… compared with placebo or no intervention (low certainty).
1 finding from 1 review
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Death by end of trial
It is very uncertain whether summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… changes all‐cause mortality ‐ at 1 year ‐ trial end compared with DFP plus deferasirox (DFX) (very low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
Summary of findings: Defibrotide showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review